Stephen Hahn

CEO, Harbinger Health & CEO-Partner, Flagship Pioneering; 24th Commissioner of U.S. FDA; former: MD Anderson

[Stephen Hahn @Stephen_M_Hahn]

@HarbingerHlth is sharing the latest in early cancer detection at @myADLM #2023AACC

[Harbinger Health @HarbingerHlth]

We are presenting three posters at #2023AACC this week! @HarbingerHlth's latest data show our technology’s strength in detecting early-stage multi-cancer screening. Read more: https://t.co/NNq1bSBp0v @myADLM

[Stephen Hahn @Stephen_M_Hahn]

Congrats to the @HarbingerHlth team on the company's progress in 2022.

[Harbinger Health @HarbingerHlth]

Looking back on 2022, we’re energized by the progress our company made and excited about what’s ahead.

Want to join us on our mission to transform cancer care, for everyone? Join our growing team: https://t.co/cEyUKfZXen

#biotech #innovation

[Stephen Hahn @Stephen_M_Hahn]

I'm grateful for the remarkable team at @HarbingerHlth for our progress this past year. #biotech #innovation

[Harbinger Health @HarbingerHlth]

We’re thrilled to be named a startup expected to take off by @BusinessInsider for our platform’s “unique insights into the biological origins of cancer, which have broad-reaching implications." Article: https://t.co/rzkF4aCnZD #CancerResearch #biotech #FlagshipFounded

[Stephen Hahn @Stephen_M_Hahn]

I'm participating to help make a difference in the future of cancer care. Thanks Dee Anna Smith @deehubie for joining me! #CancerResearch

[Harbinger Health @HarbingerHlth]

For these 2 CEOs, actions speak louder than words. Life-long cancer advocates, @Stephen_M_Hahn
& Dee Anna Smith @deehubie of
@SarahCannonDocs donated blood for our clinical study to further develop our platform for early cancer detection. Study details: https://t.co/ZVVHsq8ot1

[Stephen Hahn @Stephen_M_Hahn]

Last week Dee Anna Smith, CEO of @SarahCannonDocs, & I held fireside chats to discuss our visions for the future of cancer care. I couldn’t be more convinced that the Sarah Cannon Research Institute is the right partner for Harbinger’s CORE-HH study. #CancerResearch

[Stephen Hahn @Stephen_M_Hahn]

Great to see bipartisan progress to secure prioritized FDA support for medical innovation. The pandemic has made it clear: timely user fee reauthorization is a must to ensure the agency can effectively partner with private industry to bring lifesaving products to patients.

[Stephen Hahn @Stephen_M_Hahn]

@DGlaucomflecken Absolutely too funny